Minias (Lormetazepam)

Lormetazepam, the active ingredient in Minias, is a benzodiazepine presented as a tablet for oral use. It is prescribed for the short‑term treatment of insomnia in adult patients who have difficulty initiating or maintaining sleep. It belongs to the hypnotic class and acts by enhancing GABA‑mediated inhibition in the central nervous system.

GNH USA supplies Minias as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is manufactured under GMP conditions.

Lormetazepam is a benzodiazepine hypnotic used to manage disorders of sleep.

Insomnia (sleep onset): reduces the time required to fall asleep in adults with transient difficulty initiating sleep. Insomnia (sleep maintenance): helps maintain sleep throughout the night and reduces nocturnal awakenings. Insomnia (early morning awakening): decreases early morning awakenings and promotes a more restorative sleep period.

Common Side Effects: - Drowsiness or excessive sleepiness - Dizziness or light‑headedness - Headache - Dry mouth - Impaired coordination or balance - Fatigue

Serious or Rare Side Effects: - Dependence or withdrawal syndrome with abrupt discontinuation - Severe respiratory depression, especially when combined with other CNS depressants - Allergic reactions such as rash, angioedema, or anaphylaxis - Paradoxical agitation, aggression, or hallucinations - Significant memory impairment or amnesia

Lormetazepam should be used with caution and under medical supervision. - Dose adjustment: prescribe the lowest effective dose and limit treatment duration to avoid dependence. - Avoid alcohol: concurrent consumption may intensify central nervous system depression. - Elderly patients: increased sensitivity; monitor for falls and cognitive changes. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Renal/hepatic impairment: consider dose reduction and close monitoring. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lormetazepam may interact with several drug classes.

Major Interactions (Avoid): - Other CNS depressants (e.g., opioids, barbiturates, alcohol): risk of profound sedation and respiratory depression. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin): may increase plasma concentrations and enhance effects. - Monoamine oxidase inhibitors (MAOIs): can potentiate sedative and hypotensive actions.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin): may reduce therapeutic levels. - Concomitant benzodiazepines: additive sedation and psychomotor impairment. - Certain antidepressants (e.g., SSRIs, SNRIs): may increase overall sedation and dizziness.